- Conditions
- Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
- Interventions
- Faricimab, OLN324
- Drug
- Lead sponsor
- Ollin Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Glendale, California • Pasadena, California + 26 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 908
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Age-Related Macular Degeneration
- Interventions
- combination ranibizumab + bromfenac, ranibizumab injection alone
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Retinal Hemorrhage, Macular Degeneration
- Interventions
- vitrectomy with subretinal lucentis
- Drug
- Lead sponsor
- Corewell Health East
- Other
- Eligibility
- 50 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Royal Oak, Michigan
- Conditions
- Geographic Atrophy
- Interventions
- Tinlarebant, Placebo
- Drug
- Lead sponsor
- Belite Bio, Inc
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 429 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 19 more
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy
- Interventions
- Human Central Nervous System Stem Cells
- Biological
- Lead sponsor
- StemCells, Inc.
- Industry
- Eligibility
- 51 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Macular Edema
- Interventions
- AIV007
- Drug
- Lead sponsor
- AiViva BioPharma, Inc.
- Industry
- Eligibility
- 21 Years to 90 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 6
- States / cities
- Beverly Hills, California • Santa Ana, California • Eugene, Oregon + 3 more
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
- Interventions
- Faricimab PFS Configuration
- Combination Product
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 3
- States / cities
- Mesa, Arizona • Phoenix, Arizona
- Conditions
- Macular Edema, Uveitis
- Interventions
- triamcinolone, ranibizumab
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Macular Degeneration, Choroidal Neovascularization
- Interventions
- ranibizumab
- Drug
- Lead sponsor
- Brandon G. Busbee, MD
- Other
- Eligibility
- 50 Years to 95 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Inherited Ophthalmic Diseases, Hypopigmentation Disorder, Corneal Dystrophy, Blue-cone Monochromacy, Best Disease, Aniridia, Albinism
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 1 Day to 120 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2054
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Geographic Atrophy
- Interventions
- OCU410
- Genetic
- Lead sponsor
- Ocugen
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Coral Springs, Florida • Carmel, Indiana + 9 more
- Conditions
- Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion, Diabetic Retinopathy (DR)
- Interventions
- Chloroprocaine Ophthalmic Gel 3% (IHEEZO), Sham Subconjunctival Injection, Proparacaine Hydrochloride Ophthalmic Solution 0.5%, Lidocaine Hydrochloride Injection 2%
- Drug · Procedure
- Lead sponsor
- Harrow Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Tyler, Texas
- Conditions
- Age Related Macular Degeneration
- Interventions
- ranibizumab
- Drug
- Lead sponsor
- The New York Eye & Ear Infirmary
- Other
- Eligibility
- 51 Years to 90 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diabetic Retinopathy, Macular Degeneration
- Interventions
- intravitreal injection of infliximab
- Drug
- Lead sponsor
- Retina Research Foundation
- Other
- Eligibility
- Not listed
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Slingerlands, New York
- Conditions
- Cystoid Macular Edema
- Interventions
- Not listed
- Lead sponsor
- Retina Institute of Hawaii
- Other
- Eligibility
- Up to 90 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii
- Conditions
- Age Related Macular Degeneration, Choroidal Neovascularization
- Interventions
- ForeseeHome
- Device
- Lead sponsor
- Notal Vision Ltd.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 3
- States / cities
- Palm Beach Gardens, Florida • Baltimore, Maryland • St Louis, Missouri
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- Ranibizumab 0.5mg, Aflibercept 2.0mg
- Drug
- Lead sponsor
- Arshad Khanani
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Reno, Nevada
- Conditions
- Age-related Macular Degeneration, Cataract
- Interventions
- Lutein/zeaxanthin, DHA/EPA, Lutein/zeaxanthin and DHA/EPA
- Dietary Supplement · Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 4,203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 91
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 72 more
- Conditions
- Exudative Age-related Macular Degeneration
- Interventions
- RBM-007 Injectable Solution, Aflibercept, Sham
- Drug
- Lead sponsor
- Ribomic USA Inc
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Sacramento, California • Walnut Creek, California + 5 more
- Conditions
- Age-Related Macular Degeneration (AMD)
- Interventions
- PAN-90806 Ophthalmic Solution, Lucentis
- Drug
- Lead sponsor
- PanOptica, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 22
- States / cities
- Colorado Springs, Colorado • Winter Haven, Florida • Shawnee Mission, Kansas + 19 more
- Conditions
- ROSAH
- Interventions
- DF-003
- Drug
- Lead sponsor
- Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- Bethesda, Maryland • Durham, North Carolina • Salt Lake City, Utah
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy, Non-neovascular AMD, Non-neovascular Age-related Macular Degeneration
- Interventions
- VOY-101
- Biological
- Lead sponsor
- Perceive Biotherapeutics, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Poway, California • Sacramento, California + 9 more
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- OTX-TKI/Sham, Aflibercept/Sham
- Drug
- Lead sponsor
- Ocular Therapeutix, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 6
- States / cities
- Bakersfield, California • Oxnard, California • Altamonte Springs, Florida + 3 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Sub-retinal transplantation of MA09-hRPE cells, tacrolimus and mycophenolate mofetil, Placebo tacrolimus and mycophenolate mofetil, Sham Surgery
- Biological · Drug · Procedure
- Lead sponsor
- Astellas Institute for Regenerative Medicine
- Industry
- Eligibility
- 50 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania